Inflammation and cardiovascular disease mechanisms.
暂无分享,去创建一个
[1] S. Yusuf. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial. Commentary , 2002 .
[2] L. Hillis. Coronary artery bypass surgery: risks and benefits, realistic and unrealistic expectations. , 1995, Journal of investigative medicine : the official publication of the American Federation for Clinical Research.
[3] P. Libby,et al. Cytokines and growth factors positively and negatively regulate interstitial collagen gene expression in human vascular smooth muscle cells. , 1991, Arteriosclerosis and thrombosis : a journal of vascular biology.
[4] P. Libby,et al. Nitric oxide decreases cytokine-induced endothelial activation. Nitric oxide selectively reduces endothelial expression of adhesion molecules and proinflammatory cytokines. , 1995, The Journal of clinical investigation.
[5] M. Pfeffer,et al. Elevation of tumor necrosis factor-alpha and increased risk of recurrent coronary events after myocardial infarction. , 2000, Circulation.
[6] P. Ridker,et al. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. , 2000, The New England journal of medicine.
[7] P. Libby,et al. Inflammation and atherosclerosis: role of C-reactive protein in risk assessment. , 2004, The American journal of medicine.
[8] P. Libby. Molecular bases of the acute coronary syndromes. , 1995, Circulation.
[9] P. Libby,et al. An atherogenic diet rapidly induces VCAM-1, a cytokine-regulatable mononuclear leukocyte adhesion molecule, in rabbit aortic endothelium. , 1993, Arteriosclerosis and thrombosis : a journal of vascular biology.
[10] P. Libby,et al. Heterozygous osteopetrotic (op) mutation reduces atherosclerosis in LDL receptor- deficient mice. , 1998, The Journal of clinical investigation.
[11] E. Bolson,et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. , 2001, The New England journal of medicine.
[12] Paul Schoenhagen,et al. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. , 2004, JAMA.
[13] A. Maseri,et al. Pre-existing coronary stenoses in patients with first myocardial infarction are not necessarily severe. , 1988, European heart journal.
[14] G. V. R. Born,et al. INFLUENCE OF PLAQUE CONFIGURATION AND STRESS DISTRIBUTION ON FISSURING OF CORONARY ATHEROSCLEROTIC PLAQUES , 1989, The Lancet.
[15] A. Meinders,et al. Strong decrease of high sensitivity C-reactive protein with high-dose atorvastatin in patients with type 2 diabetes mellitus. , 2003, Atherosclerosis.
[16] M. Pfeffer,et al. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators. , 1998, Circulation.
[17] H. Florey,et al. Changes in the endothelium of the aorta and the behaviour of macrophages in experimental atheroma of rabbits. , 1958, The Journal of pathology and bacteriology.
[18] P. Libby,et al. Evidence for increased collagenolysis by interstitial collagenases-1 and -3 in vulnerable human atheromatous plaques. , 1999, Circulation.
[19] Paul M. Ridker,et al. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. , 2001, The New England journal of medicine.
[20] J. Larosa,et al. Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials. , 1999, JAMA.
[21] N Rifai,et al. Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study. , 2001, JAMA.
[22] V. Ord,et al. Macrophage colony-stimulating factor mRNA and protein in atherosclerotic lesions of rabbits and humans. , 1992, The American journal of pathology.
[23] Allen J. Taylor,et al. ARBITER: Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol: A Randomized Trial Comparing the Effects of Atorvastatin and Pravastatin on Carotid Intima Medial Thickness , 2002, Circulation.
[24] M. Pfeffer,et al. C-reactive protein levels and outcomes after statin therapy. , 2005, The New England journal of medicine.
[25] P. Constantinides. Infiltrates of activated mast cells at the site of coronary atheromatous erosion or rupture in myocardial infarction. , 1995, Circulation.
[26] P. Libby,et al. Activation of monocyte/macrophage functions related to acute atheroma complication by ligation of CD40: induction of collagenase, stromelysin, and tissue factor. , 1997, Circulation.
[27] P. Libby,et al. Macrophage colony-stimulating factor gene expression in vascular cells and in experimental and human atherosclerosis. , 1992, The American journal of pathology.
[28] P. Libby,et al. Reduction of atherosclerosis in mice by inhibition of CD40 signalling , 1998, Nature.
[29] P. Kovanen,et al. TNF-alpha and IL-1beta selectively induce expression of 92-kDa gelatinase by human macrophages. , 1996, Journal of immunology.
[30] R. Collins,et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial , 2003, The Lancet.
[31] P. Ridker,et al. Comparison of effect of intensive lipid lowering with atorvastatin to less intensive lowering with lovastatin on C-reactive protein in patients with stable angina pectoris and inducible myocardial ischemia. , 2002, The American journal of cardiology.
[32] P. Ridker,et al. Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. , 2000, Circulation.
[33] M. Trip,et al. Differential hs-CRP reduction in patients with familial hypercholesterolemia treated with aggressive or conventional statin therapy. , 2002, Atherosclerosis.
[34] P. Libby,et al. Endotoxin and tumor necrosis factor induce interleukin-1 gene expression in adult human vascular endothelial cells. , 1986, The American journal of pathology.
[35] R D Kamm,et al. Effects of fibrous cap thickness on peak circumferential stress in model atherosclerotic vessels. , 1992, Circulation research.
[36] P. Libby,et al. Differential expression of three T lymphocyte-activating CXC chemokines by human atheroma-associated cells. , 1999, The Journal of clinical investigation.
[37] R. Terkeltaub,et al. A leukocyte homologue of the IL-8 receptor CXCR-2 mediates the accumulation of macrophages in atherosclerotic lesions of LDL receptor-deficient mice. , 1998, The Journal of clinical investigation.
[38] R. Virmani,et al. Coronary artery atherosclerosis revisited in Korean war combat casualties. , 1987, Archives of pathology & laboratory medicine.
[39] Michael Ginsberg,et al. Decreased atherosclerosis in mice deficient in both macrophage colony-stimulating factor (op) and apolipoprotein E. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[40] G. Niccoli,et al. Inflammatory predictors of mortality in the scandinavian simvastatin survival study , 2000, Clinical cardiology.
[41] M. Cybulsky,et al. A major role for VCAM-1, but not ICAM-1, in early atherosclerosis. , 2001, The Journal of clinical investigation.
[42] Richard T. Lee,et al. Overexpression of Eotaxin and the CCR3 Receptor in Human Atherosclerosis: Using Genomic Technology to Identify a Potential Novel Pathway of Vascular Inflammation , 2000, Circulation.
[43] P. Libby,et al. Inhibition of CD40 signaling limits evolution of established atherosclerosis in mice. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[44] P. Libby,et al. Lipid lowering by diet reduces matrix metalloproteinase activity and increases collagen content of rabbit atheroma: a potential mechanism of lesion stabilization. , 1998, Circulation.
[45] C. Zarins,et al. Compensatory enlargement of human atherosclerotic coronary arteries. , 1987, The New England journal of medicine.
[46] AndrewJ. S. Coats. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebocontrolled trial , 2002, The Lancet.
[47] I. Charo,et al. Decreased lesion formation in CCR2−/− mice reveals a role for chemokines in the initiation of atherosclerosis , 1998, Nature.
[48] P. Libby,et al. Dietary lipid lowering reduces tissue factor expression in rabbit atheroma. , 1999, Circulation.
[49] G. Garcı́a-Cardeña,et al. Endothelial Dysfunction, Hemodynamic Forces, and Atherogenesis a , 2000, Annals of the New York Academy of Sciences.
[50] F. Luscinskas,et al. MCP-1 and IL-8 trigger firm adhesion of monocytes to vascular endothelium under flow conditions , 1999, Nature.
[51] H. Cohen,et al. Associations of elevated interleukin-6 and C-reactive protein levels with mortality in the elderly. , 1999, The American journal of medicine.
[52] François Mach,et al. Inflammation and Atherosclerosis , 2004, Herz.
[53] M. Cybulsky,et al. Endothelial expression of a mononuclear leukocyte adhesion molecule during atherogenesis. , 1991, Science.
[54] P. Libby,et al. Ligation of CD40 on Vascular Smooth Muscle Cells Mediates Loss of Interstitial Collagen via Matrix Metalloproteinase Activity , 2001, Annals of the New York Academy of Sciences.
[55] Steven E. Nissen,et al. High Prevalence of Coronary Atherosclerosis in Asymptomatic Teenagers and Young Adults: Evidence From Intravascular Ultrasound , 2001, Circulation.